tirzepatide news update Lilly's weight-loss drug removed from FDA's shortage list FDA Says Shortage of GLP-1

treatment promoter interaction: F (10,90) = 1.1900, P = 0.3083

For a lab working on neurodegeneration, that focus is exactly what you want to see first

It reports roughly 22 percent mean body weight loss over 72 weeks for tirzepatide at the highest dose in the SURMOUNT trials, against around 15 percent for semaglutide at its highest dose in the STEP trials

If youre experiencing severe side effects, then more time on the starting dose or alternative treatment options may be recommended by your doctor

Reassure based on current evidence (no excess malformation risk)

Women Without PCOS Few studies have explored GLP-1 RA effects in women without PCOS